Jan 3 (Reuters) - Nivalis Therapeutics Inc
* Nivalis Therapeutics announces review of strategic alternatives
* Nivalis Therapeutics Inc - board of directors has initiated a process to explore and review a range of strategic alternatives
* Nivalis Therapeutics Inc - board has established a special committee to explore and evaluate strategic alternatives
* Nivalis Therapeutics Inc - company also intends to streamline its operations in order to preserve its capital and cash resources
* Nivalis Therapeutics Inc says has engaged Ladenburg Thalmann & Co. Inc. To act as its strategic financial advisor for review process
* Nivalis Therapeutics - intends to complete its ongoing SNO-7 trial of cavosonstat in patients with cf who are currently taking kalydeco (ivacaftor)
* Nivalis Therapeutics - to explore and review a range of strategic alternatives to maximize stockholder value from clinical assets and cash resources
* Nivalis Therapeutics - potential strategic alternatives that may be explored include acquisition, merger, business combination other strategic deals
* Nivalis Therapeutics Inc - ongoing SNO-7 trial of cavosonstat in patients with cf is expected to be completed in Q1 of 2017 Source text for Eikon: Further company coverage:
